1 / 72

CONGENITAL INFECTIONS

CONGENITAL INFECTIONS. Dr.M.VENKATESH Nagarcoil. Definition. Infections transmitted any time during gestation excluding the last 5 to 7 days. Common infections acquired in utero are a. CMV b. Rubella c. Toxoplasma gondii d. Treponema Pallidum e. HIV f. Human parvovirus B 19.

ecollazo
Download Presentation

CONGENITAL INFECTIONS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. CONGENITAL INFECTIONS Dr.M.VENKATESH Nagarcoil

  2. Definition • Infections transmitted any time during gestation excluding the last 5 to 7 days. • Common infections acquired in utero are a. CMV b. Rubella c. Toxoplasma gondii d. Treponema Pallidum e. HIV f. Human parvovirus B19

  3. Clinical Features

  4. Clinical Features - Contd..

  5. Diagnostic Approach • Family and maternal History • Birth weight • Medical Problems of siblings • Maternal illness • Drug use • Sexual partners and sexual orientation • Information about mother’s travels • Blood transfusions.

  6. Cytomegalo Virus • Herpes virus – Family • Largest DNA genome of any known virus • Commonest congenital viral infections

  7. Incidence • 50% – 90% • Old age, low socio economic and low educational status. • Viral excretions in the cervix or urine rises during pregnancy from 3% in the first trimester to 50% during term. • Estimated sero conversion rate during pregnancy – 0.7% - 4.1%.

  8. Mode of Spread • Fetus infected primary maternal infection and reactivated maternal infections. • Infants exposed to virus - shed from cervix. • Excreted in Breast milk. • Excrete atleast one year. • Transfusion related infections

  9. Maternal Exposure and History • Child care providers • 90% of pregnant women – asymptomatic • Symptomatic - Flu like illness • Fever fatigue , Headache, Myalgia, Lymphadenitis, Pharyngitis

  10. Etiopathogenesis • Infections occurs throughout gestations • Higher incidence during first trimester

  11. Virus ↓ Placenta ↓ Placental Fibroblast ↓ Umblical Cord ↓ Kidneys ↓ Fetal Urine ↓ Amniotic Fluid ↓ Oropharynx ↓ Fetal Circulation ↓ Target Organs

  12. Laboratory Evaluations • No universal prenatal screening • Use of IgM antibody testing in mothers and infant – Limitations • Mother with reactivation as well as infection may have positive CMV IgM • IgM testing has vide variability in accuracy and reproductability • Only 10% of pregnant women transmit infection to their fetus • CMV specific IgG. - Discriminate primary from and recurrent infection

  13. Lab Evaluation • Detection of virus in organs or culture specimens at birth (or) within first 2 to 3 weeks of life. • Sensitive detection is from urine. • Rapid method of isolation - Shell viral assay. • Elevation of liver transaminases and thrombocytopenia • Urine usually contains bile but not urobilin • Peripheral Smear – red cell, inclusion bodies owl eye cells

  14. Lab Evaluation – Contd.. CT Brain • Periventricular calcification • Ventriculomegaly • Cerebellar hypoplasia • Neural migration disorders HPE • Intranuclear inclusion bodies in brain • Mono nuclear cell infiltration and diffuse fibrosis • Sub ependymal and peri ventricular necrosis and contains, heavy growth calcium

  15. Prenatal Diagnosis • Isolation of virus by amniocentesis. • A specific nucleic acid test for CMV in amniotic fluid (or) CVS via PCR.

  16. Treatment • CMV lacks enzyme thymidine kinase. This feature renders its resistanceto antiviral agents like acyclovir. • Ganciclovir – IV for 6 weeks showed a decreased in viral urine titre. Side affects : Neutropenia, Thrombocytopenia.

  17. MRI Brain

  18. Prognosis • Risk of deafness • Reduction of IQ scores • Infected infants - Asymptomatic at birth have minimal to no sequale other than potential hearing loss. • Symptomatic at birth – mortality varies from 4 – 30%. • 90% of symptomatic neonate late complications - Intellectual and developmental impairment • Small percentage chorioretinitis. • Minimal abnormalities at birth – normal at long term follow up.

  19. Preventions • No role for antiviral therapy during pregnancy • Vaccines - Progress • Basic hygiene, Hand washing for pregnant women after contact with urine, diapers, oral secretions and other body fluids

  20. Rubella RNA Virus Toga viridae family German measles

  21. Incidence • Dropped from 58 per 100,000 population in 1969 to less than 0.5 per 100,000 population in 1997 – 1998. • Maternal infection occurs from one month before conception to the second trimester and may be associated with disease in infants. • Classical findings of congenital rubella predominates with onset of maternal infection during first 8 weeks of gestation and is low after 17 weeks of gestation.

  22. Etiopathogenesis • Transmitted from person to person via respiratory droplet. • Once the oral (or) nasopharyngeal mucosa are infected, viral replication occurs in both upper respiratory tract and nasopharyngeal lymphoid tissue. • Virus spread contiguously to regional nodes, and haematogenously to distant sites. • Fetal infection is presumed to occur during maternal viraemia.

  23. Etiopathogenesis – Contd.. • Virus induced apoptosis of cells leading to cytopathic effects and virus induced inhibition of cell division. • Foetus infected with rubella demonstrate cellular damage in multiple sites and a non inflammatory necrosis in target organs including eyes, heart, brain and ears.

  24. Clinical Spectrum • LBW , Hearing loss, Heart defects, Cataracts, Hepatosplenomegaly, Microcephaly • Skin rashes – Blueberry muffin • Interstitial pneumonia

  25. Investigations • IgM titre • Rise in paired IgG titres • Isolation of rubella virus cultured from nasal, blood, throat, urine or C&F specimen, throat swab. • Detection of virus by reverse transcriptase – PCR in specimens from throat swabs; CSF, cataracts • Viruses are recovered up to 1year in life • Thrombocytopenia, Hyperbilirubinemia, Leukopenia

  26. X-ray • Large AF • Linear areas of radiolucency in long bone • Increased densities in the metaphysis • Irregular provisional zones of calcification

  27. Treatment • No specific therapy • Anemia – Blood transfusion • Seizure control • Phototherapy

  28. Treatment – Contd.. • Long Term Care – Multi disciplinary approval • Physiatrist • O.T. • Neurologic audiology monitoring • Surgical interventions as needed for cardiac malformation and cataract

  29. Prognosis • Consequences of fetal rubella infection may not be evident at birth. • Infection in 1st or 2nd trimester may lead to deafness or persistent growth restriction • Infections in 3rd trimester – IUGR • Even in the absence of MR Neuromuscular development is commonly abnormal. • Hearing loss, difficulties with balance and gait. Learning deficits and behavioral disturbances.

  30. Preventions • No effective antiviral therapy • Live attenuated rubella virus vaccines safe and effective. • Recommended for women of child bearing age in women results of both hemagglutination inhibition antibody test and a pregnancy test are negative.

  31. Viral Hepatitis Hepatitis ‘B’ – Etiopathogenisis • DNA Virus • Localised within hepatic parenchymal cells but circulates in blood stream, along with several subviral antigens from periods ranging from a few days to many years • Transplacental leakage of HBe Ag – positive maternal blood, a potential source of intrauterine infections.

  32. Viral Hepatitis – Contd.. • During persistent viremia in mother the virus or viral antigens may rarely cross the placenta to cause intrauterine infection. • Infection can occur perinatally during labour or delivery. • Most infants born to mothers infected with HBV, test negative for HBsAg at birth. • In the absence of HBs Ag positive during the first 3 months of life suggesting transmission is peripartum

  33. Clinical Manifestations • Do not show clinical signs of disease at birth. • Without immunoprophyalxis - development of chronic antigenemia. • Less commonly manifest as jaundice, fever, hepatomegaly that either recover or leads to chronic active hepatitis.

  34. Investigations • Liver enzymes and bilirubin – reflects the extent of liver damage.

  35. Investigations – Contd..

  36. Treatment • Infants born to mother known to be HBsAg Positive • First dose Vaccine within 12 hours along with HBIG. • Second dose 1 to 2 months • Third dose within 6 months

  37. Herpes Simplex • Two Types - HSV I - HSV II Neonatal herpes caused by HSV II

  38. Incidence • 20% - 45% • 1 :3500 – 10,000 • Primary genital herpes infection in a pregnant mother – 33% to 50% • Recurrent maternal infection - 1% to 3%.

  39. Etiopathogenisis • Acquire infection from maternal genital tract at the time of delivery • HSV infections acquired even during instrumentations during ophthalmologic examination for premature infants an ritual circumcision performed by Jewish. • Inability of neonatal macrophages and unstimulated neonatal lymphocytes to mediate early viral containment and a profound defect in natural killer cell cytotoxicity.

  40. Clinical Spectrum • Multiple system involvements- Liver, Lungs, Adrenalglands, Skin, CNS, Eyes • Three groups Skin – Grouped vesicles around flat irregular ulcers within erythematous base. CNS – Poor feeds, Lethargy convulsions irritability Disseminated - Jaundice, Hypotension, DIC, Shock • Very difficult to differentiate from bacterial sepsis and hence differential diagnosis for any neonate with fever during first 2 weeks of life.

  41. Investigations • Virus isolated from • Blood, conjunctiva, respiratory Secretions urine and CNS. • Mothers genital tract • Scraping of skins vesicle may show giant, multinucleated cells • Demonstration of viral antigen in cytologic smears by EIA and DFA staining provide rapid results. • CSF – cell count – Lymphocytosis, RBC, Proteins Sugar – Lower (or) Normal PCR of CSF • In disseminated disease – ALT elevated.

  42. Investigations – Contd.. • CT and MRI Brain A loss of gray matter and white matter differentiation and features of encephalitis *Dilated ventricles *Intracranial Calcification * Cystic degeneration * Parenchymal echogenecity • EEG - Abnormal

  43. Treatment • Acyclovir 60mg / kg/ day. IV q8th hourly for 2 to 3 weeks. • Herpetic conjunctivitis -Tropical ophthalmic antiviral therapy.

  44. Prognosis • Mortality 20% with treatment • Neurological abnormality develops later in 5% group • In CNS disease 4% to 14% with antiviral therapy and survivors have long term neurological sequlae. • In Disseminated Disease 80% dies. • In skin involvement recurrent crops of skin vesicles for several years. • More than 3 episode of recurrent infection in first 6 months of life – Poor neurological outcome.

More Related